Fehlauer Fabian, Tribius Silke, Höller Ulrike, Rades Dirk, Kuhlmey Antje, Bajrovic Amira, Alberti Winfried
Department of Radiation Oncology, University Hospital of Hamburg, Hamburg, Germany.
Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):651-8. doi: 10.1016/s0360-3016(02)04120-2.
To evaluate the long-term toxicity after breast-conserving therapy in women with early-stage breast cancer.
Late toxicity according to the late effects of normal tissue-subjective, objective, management, and analytic (LENT-SOMA) criteria and cosmetic outcome (graded by physicians) were evaluated in 590 of 2943 women with early-stage breast cancer who were irradiated between 1983 and 1995 using the following fractionation schedules: group A, 1983-1987, 2.5 Gy 4x/wk to 60 Gy; group B, 1988-1993, 2.5 Gy 4x/wk to 55 Gy, group C, 1994-1995, 2.0 Gy 5x/wk to 55 Gy.
LENT-SOMA Grade 3-4 toxicity was observed as follows: group A (median follow-up 171 months; range 154-222 months), fibrosis 16% (7 of 45), telangiectasia 18% (8 of 45), and atrophy 4% (2 of 45); group B (median follow-up 113 months; range 78-164 months), pain 2% (8 of 345), fibrosis 10% (34 of 345), telangiectasia 10% (33 of 345), arm edema 1% (2 of 345), and atrophy 8% (27 of 345); and group C (median follow-up 75 months, range 51-96 months, n = 200), occurrence of Grade 3-4 late morbidity <or=2%. The cosmetic outcome was very good to acceptable in 78% (35 of 45) of patients in group A, 83% (286 of 345) in group B, and 94% (187 of 200) in group C.
In our population, the long-term side effects after breast-conserving therapy were not rare, but were mainly asymptomatic. The LENT-SOMA breast module is a practical tool to assess radiation-induced long-term toxicity.
评估早期乳腺癌女性保乳治疗后的长期毒性。
根据正常组织晚期效应的主观、客观、管理和分析(LENT-SOMA)标准评估晚期毒性,并由医生对美容效果进行分级。对1983年至1995年间接受放疗的2943例早期乳腺癌女性中的590例进行了评估,采用以下分割方案:A组,1983 - 1987年,2.5 Gy,每周4次,共60 Gy;B组,1988 - 1993年,2.5 Gy,每周4次,共55 Gy;C组,1994 - 1995年,2.0 Gy,每周5次,共55 Gy。
观察到的LENT-SOMA 3 - 4级毒性如下:A组(中位随访171个月;范围154 - 222个月),纤维化16%(45例中的7例),毛细血管扩张18%(45例中的8例),萎缩4%(45例中的2例);B组(中位随访113个月;范围78 - 164个月),疼痛2%(345例中的8例),纤维化10%(345例中的34例),毛细血管扩张10%(345例中的33例),手臂水肿1%(345例中的2例),萎缩8%(345例中的27例);C组(中位随访75个月,范围51 - 96个月,n = 200),3 - 4级晚期并发症发生率≤2%。A组78%(45例中的35例)、B组83%(345例中的286例)和C组94%(200例中的187例)的美容效果为非常好至可接受。
在我们的研究人群中,保乳治疗后的长期副作用并不罕见,但主要为无症状性。LENT-SOMA乳腺模块是评估放疗引起的长期毒性的实用工具。